Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas

Cancer Genetics and Cytogenetics

Volumn 166, Issue 2, 2006, Pages 95-100

  Chow, Warren A ^a   Bedell, Victoria ^a   Gaytan, Popsie ^a   Borden, Ernest ^b   Goldblum, John ^b   Hicks, David ^b   Slovak, Marilyn L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE;

ARTICLE; CANCER GRADING; CELL NUCLEUS; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PURINE SYNTHESIS;

CHONDROSARCOMA; CHROMOSOMES, HUMAN, PAIR 9; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 33646043791     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.10.009     Document Type: Article

References (40)

1. Rizzo M., Ghert M.A., Harrelson J.M., and Scully S.P. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res 391 (2000) 224-233
2. Unni K.K. Chondrosarcoma (primary, secondary, dedifferentiated and clear-cell). Dahlin's bone tumors: general aspects and data on 11, 0877 cases. 5th ed (1996), Lippincott-Raven, Philadelphia 71-108
3. Dorfman H.D., and Czerniak B. Malignant cartilage tumors. Bone tumors (1998), Mosby, St. Louis 353-440
4. Campanacci M. Chondrosarcomas. Bone and soft tissue tumors (1990), Springer Verlag, Vienna, New York 265-343
5. Pritchard D.J., Lunke R.J., Taylor W.F., Dahlin D.C., and Medley B.E. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer 45 (1980) 149-157
6. Bierman JS, Baker LH, Randall RL. Bone cancer. NCCN Clinical practice guidelines in oncology 2005: version 2 [Internet]. National Comprehensive Cancer Network. Accessed June 9, 2005. Current update available from http://www.nccn.org/professionals/physician_gls/PDF/bone.pdf.
7. Kamatani N., Nelson-Rees W.A., and Carson D.A. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci U S A 78 (1981) 1219-1223
8. INK4, methylthioadenosine phosphorylase, and the α- and β-interferons in human pancreatic cell carcinoma cell lines and its implications for chemotherapy. Cancer Res 56 (1996) 1083-1090
9. Hori H., Tran P., Carrera C.J., Hori Y., Rosenbach M.D., Carson D.A., and Nobori T. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 56 (1996) 5653-5658
10. Backlund Jr. P.S., and Smith R.A. 5′-Methylthioadenosine metabolism and methionine synthesis in mammalian cells grown in culture. Biochem Biophys Res Commun 108 (1982) 687-695
11. Carrera C.J., Eddy R.L., Shows T.B., and Carson D.A. Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization. Proc Natl Acad Sci U S A 81 (1984) 2665-2668
12. Diaz M.O., Ziemin S., Le Beau M.M., Pitha P., Smith S.D., Chilcote R.R., and Rowley J.D. Homozygous deletion of the α- and β1-interferon genes in human and derived cell lines. Proc Natl Acad Sci U S A 85 (1988) 5259-5263
13. Kamb A., Gruis N.A., Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day III R.S., Johnson B.E., and Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436-440
14. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
15. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371 (1994) 257-261
16. Merlo A., Gabrielson E., Mabry M., Vollmer R., Baylin S.B., and Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54 (1994) 2322-2326
17. Stadler W.M., and Olopade O.I. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24 (1996) 239-244
18. Bello M.J., and Rey J.A. Chromosome aberrations in metastatic ovarian cancer: relationship with abnormalities in primary tumors. Int J Cancer 45 (1990) 50-54
19. Cowan J.M., Halaban R., and Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 80 (1988) 1159-1164
20. van der Riet P., Nawroz H., Hruban R.H., Corio R., Tokino K., Koch W., and Sidransky D. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54 (1994) 1156-1158
21. Zhang H., Chen Z.H., and Savarese T.M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-α1, interferon-β1, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet 86 (1996) 22-28
22. Dreyling M.H., Roulston D., Bohlander S.K., Vardiman J., and Olopade O.I. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 22 (1998) 72-78
23. INK4a gene in acute type adult T-cell leukemia. Int J Cancer 75 (1998) 51-56
24. Batova A., Diccianni M.B., Nobori T., Vu T., Yu J., Bridgeman L., and Yu A.L. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 88 (1996) 3083-3090
25. INK4a (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 17 (1998) 2669-2675
26. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., and Chang A.M. MTAP gene deletion in endometrial cancer. Gynecol Obstet Invest 45 (1998) 272-276
27. Illei P.B., Rusch V.W., Zakowski M.F., et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9 (2003) 2108-2113
28. Garcia-Castellano J.M., Villanueva A., Healey J.H., Sowers R., Cordon-Cardo C., Huvos A., Bertino J.R., Meyers P., and Gorlick R. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 8 (2002) 782-787
29. Jagasia A.A., Block J.A., Diaz M.O., Nobori T., Gitelis S., Inerot S.E., and Iyer A.P. Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. Cancer Lett 105 (1996) 77-90
30. Jagasia A.A., Block J.A., Qureshi A., Jagasia A.A., Block J.A., Qureshi A., Diaz M.O., Nobori T., Gitelis S., and Iyer A.P. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 105 (1996) 91-103
31. Paternoster S.F., Brockman S.R., McClure R.F., Remstein E.D., Kurtin P.J., and Dewald G.W. A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 160 (2002) 1967-1972
32. Hollstein M.D., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
33. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
34. Barker F.G., Chen P., Furman F., Aldape K.D., Edwards M.S., and Israel M.A. p16 deletion and mutation analysis in human brain tumors. J Neurooncol 31 (1997) 17-23
35. cdkN2a/ARF, acts as a tumor suppressor in a breast cancer cell line. Cancer Res 62 (2002) 6639-6644
36. Antman K., Crowley J., Balcerzak S.P., Rivkin S.E., Weiss G.R., Elias A., Natale R.B., Cooper R.M., Barlogie B., Trump D.L., Doroshow J.H., Aisner J., Pugh R.P., Weiss R.B., Cooper B.A., Clamond G.H., and Baker L.H. An Intergroup phase II randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 (1993) 1276-1285
37. Moran R.G. Roles of folylpoly-γ-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26 Suppl 6 (1999) 24-32
38. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., and Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57 (1997) 1116-1123
39. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., and Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
40. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar, Manegold C., Paul S., Paoletti P., Einhorn L., and Bunn Jr. P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597